百亿A股，重大资产重组

Core Viewpoint - Weigao Blood Purification plans to acquire 100% equity of Shandong Weigao Purui Medical Packaging Co., Ltd. through a share issuance, which is expected to constitute a major asset restructuring and related party transaction [2][5]. Group 1: Transaction Details - The acquisition is set to be announced on October 17, 2025, with the company's stock expected to be suspended from trading for no more than 10 trading days starting from October 20, 2025 [5]. - Shandong Weigao Purui was established on September 13, 2018, and its business scope includes the production and sales of Class I and II medical devices, as well as the manufacturing of medical packaging materials [5]. - The counterparties for this transaction include Shandong Weigao Group Medical Polymer Co., Ltd., Weihai Shengxi Enterprise Management Consulting Center (Limited Partnership), and Weihai Ruiming Enterprise Management Consulting Partnership (Limited Partnership) [5]. Group 2: Company Background - Weigao Blood Purification was listed on the Shanghai Stock Exchange on May 19, 2025, focusing on the research, production, and sales of blood purification medical products, including blood dialysis devices and solutions [8]. - As of June 30, 2025, Shandong Weigao Group is the largest shareholder of Weigao Blood Purification, holding 41.75% of the shares, while Shandong Weigao Group Medical Polymer Co., Ltd. holds 23.9% [8]. Group 3: Financial Performance - In the first half of 2025, Weigao Blood Purification achieved a revenue of 1.765 billion yuan, representing a year-on-year growth of 8.52%, and a net profit attributable to shareholders of 220 million yuan, up 10.11% year-on-year [10]. - As of October 17, 2025, Weigao Blood Purification's stock price was 38.61 yuan per share, with a market capitalization of 16.13 billion yuan [11].